Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01261325 · ClinicalTrials.gov registry record · Phase 3
Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures
A Phase 3 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 768
- Enrollment target
NCT01261325: Completed Phase 3 study, sponsored by UCB Pharma.
NCT01261325 is a Phase 3 study that has completed, run by UCB Pharma. The registered enrollment target is 768 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01261325, a Phase 3 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 768 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of brivaracetam at doses of 100 and 200mg/day compared to placebo as adjunctive treatment in adult focal epilepsy subjects with partial onset seizures not fully controlled despite current treatment with 1 or 2 concomitant antiepileptic drugs.
Primary Outcome
Primary endpoint: United States of America (FDA)
Interventions
- DRUG Placebo
- DRUG Brivaracetam
- DRUG Antiepileptic drugs with market authorization available per country
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 768 participants |
| Start Date | 2010-12 |
| Est. Completion | 2014-05 |
| Phase | Phase 3 |
What the finished NCT01261325 record still lists
NCT01261325 is an interventional study that assigns participants to a tested intervention. The registered 768 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01261325 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01261325 about?
NCT01261325 is a clinical study titled "Brivaracetam Efficacy and Safety Study in Subjects With Partial Onset Seizures". This study will evaluate the efficacy and safety of brivaracetam at doses of 100 and 200mg/day compared to placebo as adjunctive treatment in adult focal epilepsy subjects with partial onset seizures not fully controlled despite current treatment with 1 or 2 concomitant antiepileptic drugs.
What is the current status of trial NCT01261325?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 768 participants. The study started on 2010-12. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01261325?
The interventions under investigation include: Placebo (DRUG), Brivaracetam (DRUG), Antiepileptic drugs with market authorization available per country (DRUG).
Who is sponsoring clinical trial NCT01261325?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01261325's enrollment target sits among peer trials
768 445th of 2000 higher than 1,556 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05119556 · 768 participants · NA
Video Telehealth Pulmonary Rehabilitation to Reduce Hospital Readmission in Chronic Obstructive Pulmonary Disease
- NCT05404750 · 768 participants
Harm Reduction in HIV Primary Care for PLWH Who Use Drugs
- NCT05660525 · 768 participants · NA
Leveraging Community Pharmacists to Optimize Smoking Cessation Services for Rural Smokers in Appalachia
- NCT06324357 · 768 participants · Phase 1
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia